Previous Article | Next Article 
Journal of Clinical Microbiology, December 1998, p. 3567-3573, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Differentiation of Campylobacter jejuni
Serotype O19 Strains from Non-O19 Strains by PCR
Naoaki
Misawa,1
Ban Mishu
Allos,1 and
Martin J.
Blaser1,2,*
Division of Infectious Diseases, Vanderbilt
University School of Medicine, Nashville, Tennessee
37232-2605,1 and
Department of Veterans
Affairs Medical Center, Nashville, Tennessee 372122
Received 7 May 1998/Returned for modification 17 August
1998/Accepted 23 September 1998
 |
ABSTRACT |
Guillain-Barré syndrome (GBS), a neurologic disease
characterized by acute paralysis, is frequently preceded by
Campylobacter jejuni infection. Serotype O19 strains are
overrepresented among GBS-associated C. jejuni isolates. We
previously showed that all O19 strains tested were closely related to
one another by randomly amplified polymorphic DNA (RAPD) and
restriction fragment length polymorphism analyses. RAPD analysis
demonstrated a 1.4-kb band in all O19 strains tested but in no non-O19
strains. We cloned this O19-specific band; nucleotide sequence analysis
revealed a truncated open reading frame with significant homology to
DNA gyrase subunit B (gyrB) of Helicobacter
pylori. PCR using the random primer and a primer specific for
gyrB showed that in non-O19 strains, the random primer did
not recognize the downstream gyrB binding site. The regions
flanking each of the random primer binding sites were amplified by
degenerate PCR for further sequencing. Although the random primer had
several mismatches with the downstream gyrB binding site, a
single nucleotide polymorphism 6 bp upstream from the 3' terminus was
found to distinguish O19 and non-O19 strains. PCR using 3'-mismatched
primers based on this polymorphism was designed to differentiate O19
strains from non-O19 strains. When a total of 42 (18 O19 and 24 non-O19) strains from five different countries were examined, O19
strains were distinguishable from non-O19 strains in each case. This
PCR method should permit identification of O19 C. jejuni strains.
 |
INTRODUCTION |
Guillain-Barré syndrome (GBS)
is a neurologic disease characterized by ascending paralysis that can
lead to respiratory muscle compromise and death (3, 11).
Although the exact trigger of GBS is unknown, case control studies have
shown that GBS is frequently preceded by acute infectious illness
(11, 21). In recent decades, serologic and cultural studies
have suggested that Campylobacter jejuni infection is one of
the most important triggers of GBS (2, 5, 23). Culture
confirmation of preceding C. jejuni infection in 8 to 50%
of GBS patients has been achieved (2), despite the fact that
many GBS patients with antecedent Campylobacter infection
are likely to have already cleared their stools by the time neurologic
symptoms begin.
C. jejuni strains isolated from the stools of patients with
GBS include Penner serotypes O1, O2, O10, O19, O41, and O64 (8, 13, 14, 17, 28). Among the diverse lipopolysaccharide molecules
of C. jejuni strains, some structures closely resemble human
gangliosides (4, 22, 30, 41-43), suggesting that molecular mimicry could trigger the neuronal injury observed in GBS. O19 strains
account for 83 and 29% of GBS-associated C. jejuni isolates in Japan (8, 14) and the United States (3),
respectively, but for <3% of C. jejuni isolates from
patients with uncomplicated gastroenteritis in both countries (25,
26). About one of every thousand Campylobacter
infections of any serotype results in GBS; however, the risk of
developing GBS after infection with an O19 C. jejuni strain
is estimated to be about 1 in 158 (2). We hypothesized that
O19 strains (especially those isolated from GBS patients) have close
genetic relationships to one another and that they may represent a
particularly virulent clone. To test this hypothesis, the genetic
variation among GBS-associated C. jejuni and
enteritis-associated (control) strains was determined by randomly
amplified polymorphic DNA (RAPD) and restriction fragment length
polymorphism (RFLP) analyses (7). Although each of the non-O19 strains had a unique pattern, whether they shared O or Lior
serotypes, all O19 strains tested were closely related, regardless of
Lior serotype, country of origin, or whether they were GBS associated
(7). RAPD analysis using primer D14307 (1)
revealed a 1.4-kb band shared by all O19 strains tested, but not in the non-O19 strains (7). We now ask whether genetic differences can be used to distinguish O19 from non-O19 strains for clinical purposes. Our goals in the present study were to clone the O19-specific RAPD band, to determine its nucleotide sequence, and to define differences between O19 and non-O19 strains. As a result of these studies, a PCR technique using 3'-mismatched primers (9, 15, 19) that differentiates O19 from non-O19 strains was developed.
 |
MATERIALS AND METHODS |
Bacterial strains and culture conditions.
A total of 42 C. jejuni strains, including 18 O19 strains and 24 strains
of other serotypes, isolated from patients with GBS or with
uncomplicated enteritis in five different countries were used in this
study (Table 1). Strains were suspended
in brucella broth (BBL Microbiology Systems, Cockeysville, Md.)
containing 15% glycerol (Sigma Chemical Co., St. Louis, Mo.) and
stored at
70°C until tested. The thawed bacteria were cultured
microaerobically (10% CO2, 5% O2 and 85%
N2) on Trypticase soy agar containing 5% sheep blood (BBL)
at 37°C for 48 h. The strains had been typed according to the
Penner (O) (27) and Lior (18) serotyping schemes
described previously (7). C. jejuni D450 (O19 and
GBS), D3083 (O19 and non-GBS), 84-196 (non-O19 and GBS), and 85-1 (non-O19 and non-GBS) strains (Table 1) were used for the DNA sequence analyses. Escherichia coli DH5
was grown in L broth or on
L plates (31).
Genetic techniques.
Bacteria were grown on blood agar plates
for 48 h, and chromosomal DNA was prepared as described previously
(7). Plasmids were isolated by using the QIAprep Spin
Plasmid Kit (Qiagen Inc. Chatsworth, Calif.) as specified by the
manufacturer. DNA fragments from agarose gels were extracted with
QIAquick Gel Extraction Kit (Qiagen), and PCR products were purified
with the QIAquick PCR Purification Kit (Qiagen). All other standard
molecular genetic techniques were used as described elsewhere
(31). The nucleotide sequence was determined with an ABI
automated sequencer (Applied Biosystems, Inc., Foster City, Calif.) in
the Vanderbilt University Cancer Center Core Facility. Oligonucleotide
primers listed in Table 2 were
synthesized with an ABI 392 DNA synthesizer (Applied Biosystems).
Computer analysis of DNA and protein sequences were performed with the
Genetics Computer Group programs; database similarity searches were
performed through the National Center for Biotechnology Information by
use of the BLASTX algorithm.
PCR techniques.
PCR techniques used in this study are
schematically shown in Fig. 1.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representations of PCR techniques used in this
study. (A) An O19-specific band was amplified by RAPD PCR using primer
D14307, as previously described (7). (B) Random primer
D14307 was paired with a specific primer (A8683 or B7493) to determine
whether the random primer recognizes an analogous binding site among
non-O19 strains. (C) To determine the sequences of the regions flanking
each D14307 binding site, degenerate primers (AN024 or AN025) were
paired with nondegenerate primers (AN076 or AN077). After sequencing
from the nondegenerate primer binding site, new primers (AN263 and
C3648) specific to each region flanking the degenerate primer binding
sites were designed and then nondegenerate PCR was performed. (D) To
differentiate O19 strains from non-O19 strains, specific PCR primers
for each group were designed. Oligonucleotide primers (14- or 18-mer)
terminating at the mismatched sequences observed in the gyrB
alleles were synthesized. Primer C3647 or C3648 was paired with each of
these specific primers. The random primer (D14307) and degenerate
primer binding sites are indicated by hatched areas R and D1 or D2,
respectively.
|
|
(i) RAPD PCR.
RAPD PCR was conducted by using the 20-mer
oligonucleotide D14307, as described previously (1), except
for minor modifications. In brief, PCR was performed in a DNA thermal
cycler (Perkin-Elmer Cetus, Norwalk, Conn.) in reaction mixtures of 25 µl containing 20 ng of genomic DNA, 2.5 µl of 10× reaction buffer
(Qiagen), 3 mM MgCl2, 160 pM primer, 0.625 U of
Taq DNA polymerase (Qiagen), and 250 µM each of the four
deoxynucleotides, under mineral oil. The PCR program was as follows:
(i) 4 cycles, with 1 cycle consisting of 5 min at 94°C, 5 min at
40°C, and 5 min at 72°C, (ii) 30 cycles, with 1 cycle consisting of
1 min at 94°C, 1 min at 55°C, and 2 min at 72°C, and (iii)
incubation at 72°C for 10 min to complete the extension. The
resulting amplicons were separated by electrophoresis in 1% agarose
gels. The 1.4-kb O19-specific band was cloned into pT7Blue (Novagene,
Madison, Wis.) to create pTIC120 (strain D450) or pTIC121 (strain D3083).
(ii) Specific PCR.
After sequence analysis of the
O19-specific band, new primers specific for the fragment were designed
(Table 2). PCR was performed to determine why random primer D14307
failed to amplify a 1.4-kb band in non-O19 strains. Primer A8683 or
B7493 was used as a specific upstream or downstream primer. We
confirmed that each of these specific primers was able to recognize
both O19 and non-O19 strains. To determine whether D14307 bound to
either primer binding site among non-O19 strains, PCR amplification was performed for 30 cycles, with 1 cycle consisting of denaturation at
94°C for 1 min, annealing at 50°C for 1 min, and extension at
72°C for 2 min, followed by extension at 72°C for 10 min. The PCR
mixture was prepared as described for the RAPD PCR above, except that
the concentration of MgCl2 was reduced to 1.5 mM. Six O19
and non-O19 strains were used in this experiment.
(iii) Degenerate PCR.
Nucleotide and amino acid sequence
analyses of the 1.4-kb amplicon revealed a truncated open reading frame
homologous to known DNA gyrase subunit B (gyrB) (see below).
To determine the sequences of the regions flanking each D14307 binding
site, degenerate primers were designed and paired with nondegenerate
primers. The degenerate primers were synthesized based on conserved
amino acid sequences of GyrB from Helicobacter pylori
(GenBank accession no. P55923), E. coli (GenBank accession
no. P06982), and Salmonella typhimurium (GenBank accession
no. Q60008). For the upstream primer binding region within
gyrB, the forward degenerate primer AN024, based on the
conserved amino acid sequence GMYIGDT, was paired with the reverse
specific primer AN076 (Fig. 1). For the downstream primer binding
region within gyrB, the reverse degenerate primer AN025,
based on conserved amino acid sequence LWETTM, was paired with the
specific forward primer AN077. The target DNA was amplified for 30 cycles of PCR, with 1 cycle consisting of denaturation at 94°C for 1 min, annealing of primers for 2 min at 37°C, and primer extension for
3 min at 72°C. The amplicons from two O19 strains (D450 and D3083)
were extracted from agarose gels and then purified. After sequencing
from the nondegenerate primer binding site, new primers (AN263 and
C3648) specific to each region flanking the degenerate primer binding
sites were designed and then nondegenerate PCR was performed.
Nucleotide sequences of the amplicons from two O19 (D450 and D3083) and
non-O19 (84-196 and 85-1) strains were compared.
(iv) PCR using 3'-mismatched primers.
To differentiate O19
from non-O19 strains, PCR using 3'-mismatched primers, a procedure
reported to discriminate chromosomal point mutations (9, 15,
19), was adopted. Oligonucleotide primers based on a polymorphic
gyrB sequence that differed between O19 and non-O19 strains
were synthesized. The 3'-terminal nucleotides of the 14- or 18-mer
oligonucleotides were exactly complementary to either O19 or non-O19
target sequences (Table 2). Primer C3647 (forward) or C3648 (reverse)
was used with each specific primer. In preliminary experiments, these
primers were confirmed to PCR amplify the expected band in both O19 and
non-O19 strains (data not shown). The allele-specific PCRs were
performed in a 25-µl reaction volume including 10× PCR buffer, 0.625 U of Taq DNA polymerase, 80 pM primer, 250 µM each of the
four deoxynucleotides, and 20 ng of template DNA. To evaluate
appropriate PCR conditions for distinguishing O19 strains from non-O19
strains, initially two O19 and two non-O19 strains were studied; the
annealing temperature was varied, and the resulting amplicons from all
strains were compared. The optimal PCR program examined (data not
shown) consisted of 40 cycles of PCR, with 1 cycle consisting of
denaturation at 94°C for 1 min, annealing for 1 min, and extension at
72°C for 1 min.
Nucleotide sequence accession number.
The 2,055-nucleotide
sequence in gyrB was deposited in GenBank data bank under
accession no. AF093760.
 |
RESULTS |
Cloning and sequencing of the O19-specific band.
We confirmed
our previous result (7), that by RAPD PCR using random
primer D14307, a 1.4-kb fragment was detected in two O19 strains but
not in two non-O19 strains (data not shown). The O19-specific band was
extracted from agarose gels and cloned into pT7Blue. Nucleotide
sequence analysis of the cloned amplicons from two O19 strains (D450
and D3083) revealed the presence of an open reading frame of at least
1,431 nucleotides. A search for amino acid sequence homologies revealed
that this O19-specific fragment has 64% identity with the DNA gyrase
subunit B (encoded by gyrB) of H. pylori.
Comparison with the H. pylori sequence showed that the
C. jejuni fragment did not contain the nucleotides encoding
either the N- or C-terminal region of the intact protein.
Specific PCR analysis.
We then sought to determine whether the
difference between O19 and non-O19 strains by RAPD PCR might be
attributed to mismatched sequences at the sites in gyrB at
which D14307 could bind. To confirm our hypothesis, new primers (A8683
and B7493) which bind to both O19 and non-O19 strains were synthesized.
When D14307 was used as the 5' primer with A8683 as the 3' primer, a
band of the expected (0.3-kb) size was detected in all six O19 strains and in two of six non-O19 strains (Fig.
2). In contrast, when D14307 was used as
the 3' primer and B7493 was the 5' primer, a band of the expected
(1.1-kb) size was amplified in all O19 strains but in none of the
non-O19 strains (Fig. 2). These results suggest that the downstream
D14307 binding site of gyrB is important in differentiating
O19 from non-O19 strains by RAPD PCR.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 2.
PCR of 12 C. jejuni isolates using random
primer D14307 and primers specific for gyrB. O19 isolates
(lanes 1 to 6) and non-O19 isolates (lanes 8 to 13) from patients with
GBS (lanes 1 to 3 and 8 to 10) or diarrhea (lanes 4 to 6 and 11 to 13)
were used. (A) PCR using D14307 (forward) and specific primer A8683
(reverse). (B) PCR using specific primer B7493 (forward) and D14307
(reverse). Lanes 7 and 14 are the no-DNA control. Lane M contains the
1-kb ladder markers. The positions (in kilobases) of molecular size
markers are indicated to the left of the gel.
|
|
Degenerate PCR analysis.
To determine the exact sequences of
both the upstream and downstream D14307 binding regions within
gyrB, we first designed degenerate PCR primers that flank
the expected sites. Since all fragments amplified by RAPD PCR were
originally extended from primer D14307, the binding sites would not be
expected to reflect exact sequences if D14307 mismatched the template
DNA. Paired degenerate and nondegenerate primers were used to amplify a
DNA fragment that flanked each region (Fig. 1). A band of the expected size (0.3 or 0.5 kb for the targeted upstream or downstream fragments, respectively) in each degenerate PCR was detected in each of the two
O19 strains (D450 and D3083) tested (data not shown). Each band was
extracted from an agarose gel, and sequences were analyzed directly
with the specific primers. Next, new specific primers adjacent to the
degenerate primer binding region were synthesized. The two pairs of
specific primers also amplified bands of the expected size in each of
two O19 (D450 and D3083) and non-O19 (84-196 and 85-1) strains
(data not shown). In total, we sequenced 2,055 nucleotides within
gyrB, using the above combination of amplicons.
Sequence analysis of the O19-specific fragment.
Comparison of
the sequences of the four PCR amplicons for the two regions showed only
small differences among the O19 and non-O19 strains tested (Fig.
3). When the sequences
of D14307 and each binding site in the O19 strains were compared, 7 or
8 of 20 nucleotides at the upstream or downstream binding site, respectively, were mismatched. Nevertheless, most nucleotides at the 3'
end of each binding site were completely matched (Fig. 3). In the
upstream gyrB D14307 binding site, the sequences of two O19
strains and one of the two non-O19 strains were identical, except for a
single nucleotide difference (C or T) 2 bp upstream of the 3' terminus
of the binding region in strain 85-1 (Fig. 3). Similarly, in the
downstream gyrB D14307 binding site, a single nucleotide
polymorphism (A or G) 6 bp upstream of the 3' terminus of the binding
region was found in the O19 and non-O19 strains tested (Fig. 3). The
results of the RAPD PCR and the PCR using the combination of a random
primer and a specific primer with the non-O19 strains suggest that
D14307 is not able to recognize the downstream binding site present in
O19 strains due to a single nucleotide difference in the template DNA.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of the nucleotide sequences of
gyrB among O19 (D450 and D3083) and non-O19 strains (84-196 and 85-1). Fragments initially were amplified by degenerate PCR (Fig.
1), then new primers (AN263 and C3648) specific to each region were
designed, and specific PCR was then performed for further sequencing.
Fragments of 353 bp near the upstream end (A) and of 508 bp near the
downstream end (B) of gyrB were amplified in all strains
tested. Nucleotides identical to those in D450 are indicated by dots.
Each D14307 binding site is enclosed in a box. The sequence of random
primer D14307 is shown in italics under the box indicating its binding
site. PCR primers with the 3' end mismatched in relation to the
position indicated with an asterisk were designed to differentiate O19
strains from non-O19 strains.
|
|
PCR specific for O19 or non-O19 strains.
Because this single
nucleotide difference at the downstream D14307 binding region in
gyrB discriminated between O19 and non-O19 strains, we
adopted a PCR method that was developed to directly screen for
site-directed genomic polymorphisms (15, 19). New downstream
binding site primers were designed so that the only difference between
the O19- and non-O19-specific primers was the 3'-terminal nucleotide
(Table 2). To begin, we used two O19 and two non-O19 strains to
optimize PCR conditions and programs. When short 5' and 3' primers or
long 5' primers were used as specific primers, either no PCR product
was amplified or the O19 and non-O19 strains were not completely
differentiated, even with variation in annealing temperatures. With
other test conditions, the groups were distinguishable, but different
PCR programs had to be run for each group (data not shown). In
contrast, when the long O19-specific primer oligonucleotide (C3650) was
used as the 3' primer and C3647 was used as the 5' primer and annealed
at 48°C, the O19-specific band was detected. However, a faint band
also was amplified for the non-O19 strains. By increasing the annealing
temperature to 50°C, the band was not detected in the non-O19 strain,
but the O19-specific band had become faint. However, when the long
non-O19 specific oligonucleotide (C3652) was used as a 3' primer,
specific bands were detected at both annealing temperatures and no O19 band was amplified. We next combined two PCR programs to eliminate nonspecific amplification and to amplify the specific band. The new PCR
program was performed as follows: 10 cycles, with 1 cycle consisting of
1 min at 94°C, 1 min at 50°C, and 1 min at 72°C, followed by 30 cycles, with 1 cycle consisting of 1 min at 94°C, 1 min at 48°C,
and 1 min at 72°C. Using this single program, O19 and non-O19 strains
were clearly differentiated by each specific primer (C3650 or C3652,
respectively) in conjunction with C3647 (Fig.
4). A total of 42 strains, including 18 O19 strains and 24 non-O19 strains, were examined under the PCR
conditions determined to be optimal. All O19 and non-O19 strains tested
were distinguished, and there was no nonspecific amplification (Table
1). Each 3' primer specific for the O19 or non-O19 strains amplified
two bands, even though they were specific to each group of strains.
Although one band (0.4 kb) was of the expected size, the second
(0.3-kb) band was unexpected based on the locations of each specific
primer (C3650 or C3652) in conjunction with C3647. We thus hypothesized that another region highly homologous to the primer binding site might
exist in gyrB. Further analysis demonstrated a sequence (5'-TTATTTAAAAGATGAAAA-3') that was highly homologous to the
downstream binding site (5'-AATTTTAAAAGATCTTGA-3') and was
123 bp upstream of it. These data indicate that in conjunction with
C3647, the specific primers used also bound to this second genomic
sequence, yielding the second (0.3-kb) band.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 4.
Successful PCR discrimination between O19 and non-O19
strains using O19 (A) or non-O19 (B) specific primers to
gyrB. O19 isolates (lanes 1 to 6) and non-O19 isolates
(lanes 7 to 12) from patients with GBS (lanes 1 to 3 and 7 to 9) or
enteritis (diarrhea alone) (lanes 4 to 6 and 10 to 12) were used.
Strain designations for the lanes are as follows: lane 1, D450 (O19);
lane 2, 84-158 (O19); lane 3, OH4382 (O19); lane 4, D3083 (O19); lane
5, D3180 (O19); lane 6, D3145 (O19); lane 7, 84-196 (O2); lane 8, 84-197 (O8, O17); lane 9, 86-381 (O2); lane 10, 84-194 (O16, O50); lane
11, 85-1 (O1); lane 12, 81116 (O6). Lane 13 is the no-DNA control. Lane
M contains the 1-kb ladder markers. The positions (in kilobases) of
molecular size markers are indicated to the left of the gel.
|
|
 |
DISCUSSION |
This study was initiated to search for genetic differences between
O19 and non-O19 strains. In a previous study (7), we demonstrated that all O19 strains tested were closely related to one
another and we identified O19-specific bands by RAPD analysis. Thus,
RAPD analysis (37) is a useful tool for scanning the entire genome to look for differences between strains of C. jejuni
(10, 20) as reported in other bacterial pathogens (6,
36).
In this study, we successfully extracted, cloned, and sequenced one
O19-specific band that shows significant homology to gyrB in
H. pylori (33). Because gyrB is
essential for bacterial viability (34), we sought to
determine whether the random primer used in this study (D14307) was
able to bind to gyrB in non-O19 strains. The fact that
D14307 was able to recognize the upstream binding site but not the
downstream site within gyrB in some non-O19 strains suggests
that the D14307 downstream binding sites may be important in
differentiating O19 from non-O19 strains. Next, gyrB regions were amplified by degenerate PCR to allow sequence analysis of each
D14307 binding site. In total, we determined about 90% of the overall
sequence (2,055 bp) of gyrB in C. jejuni compared to 2,319 bp of gyrB in H. pylori 26695 (33). Sequence analysis revealed that both nucleotide and
amino acid sequences were highly conserved among the O19 and non-O19
strains tested. The fact that the sequences of O19 strains D450 and
D3083 were identical even though the strains were obtained from
different clinical settings and had different Lior serotypes is
consistent with the close genetic relationship among O19 strains
previously postulated (7). In contrast, non-O19 strains
84-196 and 85-1 had small differences at the nucleotide level, which is
consistent with the known high degree of genetic diversity in C. jejuni (16, 24). However, nearly all the differences in
nucleotide sequences were synonymous.
When the sequences in the random primer D14307 and both binding sites
in O19 strains were compared, several nucleotide mismatches were found.
The fact that several nucleotides toward the 3' end of D14307 and each
binding site were completely matched was apparently sufficient for
initiation of PCR despite the mismatches at each 5' end. The fact that
the difference between O19 and non-O19 strains in the downstream D14307
binding region consists of a single polymorphism near the 3' terminus
indicates that this single difference, in the context of the numerous
mismatches, was sufficient to prevent annealing to the template.
Although O19 and non-O19 strains are distinguishable by RAPD PCR
(12), a PCR method using specific primers is more desirable for maximizing accuracy of diagnosis. Since efficient PCR amplification requires a primer whose 3'-terminal nucleotide is complementary to the
target sequence (38), we adopted a PCR method using 3'-end mismatched primers to differentiate the strains. Specific PCR conditions, including reagents, annealing temperature, and primer length, were optimized, leading to a method specific for
differentiating O19 and non-O19 strains that can be performed under
identical conditions and that will facilitate rapid laboratory
diagnosis. Modifications in the PCR reagents, such as decreasing the
deoxynucleoside triphosphate or magnesium level, which have been
reported to improve discrimination (15), were not necessary.
PCRs using two different sets of primers are advantageous by yielding
one positive and one negative signal regardless of the allele. The
reproducible results of the screening test using 42 strains from
different parts of the world suggest the broad utility of these
genotypic methods, although more-exhaustive studies will be needed to
completely define the method's accuracy. The constancy in genotypes of
O19 strains at this single locus as well as our previous RAPD and RFLP
results (7) contrasts with reported phenotypic differences in lipopolysaccharide structure (29, 30). Use of this PCR method, as opposed to RAPD PCR, which may be difficult to standardize, or serotyping, which is not widely available, should make detection of
O19 strains available to most clinical microbiology laboratories.
DNA gyrase consists of two A and two B subunits which are encoded by
the genes gyrA and gyrB, respectively
(34). High-level resistance of Campylobacter spp.
to the fluoroquinolones and nalidixic acid, which are DNA gyrase
inhibitors, has been reported (12). Mutations conferring
quinolone resistance in E. coli were found in both
gyrA and gyrB (39, 40). However,
alterations in GyrA rather than GyrB are associated with high-level
resistance in Campylobacter spp. (12, 32).
Similarly, for C. jejuni strains, gyrA mutations
causing changes at Ala-70, Thr-86, and Asp-90 in the protein resulted
in nalidixic acid resistance (35). In the present study, the
nucleotide difference found in the 3'-primer binding region did not
affect the amino acid sequence and does not determine the quinolone
susceptibility phenotype. Thus, the differences we found between O19
and non-O19 strains are independent of fluoroquinolone resistance.
 |
ACKNOWLEDGMENTS |
This study was supported in part by a Center grant from the
National Cancer Institute (CA68485), grant K08-NS01709 from the National Institutes of Health (NINDS), the Medical Research Service of
the Department of Veterans Affairs, and by the Iris and Homer Akers
Fellowship in Infectious Diseases (to N.M.).
We thank Richard Hughes, Jeremy Rees, and Manfred Kist for providing strains.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Infectious Diseases, Vanderbilt University School of Medicine, A-3310
Medical Center North, Nashville, TN 37232-2605. Phone: (615) 322-2035. Fax: (615) 343-6160. E-mail:
Martin.Blaser{at}mcmail.vanderbilt.edu.
 |
REFERENCES |
| 1.
|
Akopyanz, N.,
N. O. Bukanov,
T. U. Westblom,
S. Kresovich, and D. E. Berg.
1992.
DNA diversity among clinical isolates of Helicobacter pylori detected by PCR-based RAPD fingerprinting.
Nucleic Acids Res.
20:5137-5142[Abstract/Free Full Text].
|
| 2.
|
Allos, B. M., and M. J. Blaser.
1995.
Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome.
J. Endotoxin Res.
2:237-238.
|
| 3.
|
Allos, B. M.,
F. T. Lippy,
A. Carlsen,
R. G. Washburn, and M. J. Blaser.
1998.
Campylobacter jejuni strains from patients with Guillain Barré syndrome.
Emerg. Infect. Dis.
4:263-268[Medline].
|
| 4.
|
Aspinall, G. O.,
S. Fujimoto,
A. G. McDonald,
H. Pang,
L. A. Kurjanczyk, and J. L. Penner.
1994.
Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barré syndrome mimic human gangliosides in structure.
Infect. Immun.
62:2122-2125[Abstract/Free Full Text].
|
| 5.
|
Enders, U.,
H. Karch,
K. V. Toyka,
J. Heeseman, and H. P. Hartung.
1994.
Campylobacter jejuni and Guillain-Barré syndrome.
Ann. Neurol.
35:248-249[Medline].
|
| 6.
|
Fadl, A. A.,
A. V. Nguyen, and M. I. Khan.
1995.
Analysis of Salmonella enteritidis isolates by arbitrarily primed PCR.
J. Clin. Microbiol.
33:987-989[Abstract].
|
| 7.
|
Fujimoto, S.,
B. M. Allos,
N. Misawa,
C. M. Patton, and M. J. Blaser.
1997.
Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barré syndrome.
J. Infect. Dis.
176:1105-1108[Medline].
|
| 8.
|
Fujimoto, S.,
N. Yuki,
T. Itoh, and K. Amako.
1992.
Specific serotypes of Campylobacter jejuni associated with Guillain-Barré syndrome.
J. Infect. Dis.
165:183[Medline].
|
| 9.
|
Ge, Z., and D. E. Taylor.
1997.
Rapid polymerase chain reaction screening of Helicobacter pylori chromosomal point mutations.
Helicobacter
2:127-131[Medline].
|
| 10.
|
Hilton, A. C.,
D. Mortiboy,
J. G. Banks, and C. W. Penn.
1997.
RAPD analysis of environmental, food and clinical isolates of Campylobacter spp.
FEMS Immunol. Med. Microbiol.
18:119-124[Medline].
|
| 11.
| Hughes, R. A. C., and J. H. Rees.
1997. Clinical and epidemiologic features of Guillain-Barré
syndrome. J. Infect. Dis. 176(Suppl.
2):S92-S98.
|
| 12.
|
Husmann, M.,
A. Feddersen,
A. Steitz,
C. Freytag, and S. Bhakdi.
1997.
Simultaneous identification of campylobacters and prediction of quinolone resistance by comparative sequence analysis.
J. Clin. Microbiol.
35:2398-2400[Abstract].
|
| 13.
|
Jacob, B. C.,
M. P. Hazenberg,
P. A. van Doorn,
H. Endtz, and F. G. A. van der Meché.
1997.
Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré syndrome or Miller Fisher Syndrome.
J. Infect. Dis.
175:729-733[Medline].
|
| 14.
|
Kuroki, S.,
T. Saida,
M. Nukina,
T. Haruta,
M. Yoshioka,
Y. Kobayashi, and H. Nakanishi.
1993.
Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain -N-acetylglucosamine residues.
Ann. Neurol.
33:243-247[Medline].
|
| 15.
|
Kwok, S.,
D. E. Kellogg,
N. McKinney,
D. Spasic,
L. Goda,
C. Levenson, and J. J. Sninsky.
1990.
Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies.
Nucleic Acids Res.
18:999-1005[Abstract/Free Full Text].
|
| 16.
|
Lam, K. M.,
R. Yamamoto, and A. J. DaMassa.
1995.
DNA diversity among isolates of Campylobacter jejuni detected by PCR-based RAPD fingerprinting.
Vet. Microbiol.
45:269-274[Medline].
|
| 17.
| Lastovica, A. J., E. A. Goddard, and A. C. Argent. 1997. Guillain-Barré syndrome in South Africa
associated with Campylobacter jejuni O:41 strains. J. Infect. Dis. 176(Suppl. 2):S139-S143.
|
| 18.
|
Lior, H.,
D. L. Woodward,
J. A. Edgar,
L. J. Laroche, and P. Gill.
1982.
Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors.
J. Clin. Microbiol.
15:761-768[Abstract/Free Full Text].
|
| 19.
|
Major, J. J. G.
1992.
A rapid PCR method of screening for small mutations.
BioTechniques
12:40-44.
|
| 20.
|
Mazurier, S.,
A. van de Giessen,
K. Heuvelman, and K. Wernars.
1992.
RAPD analysis of Campylobacter isolates: DNA fingerprinting without the need to purify DNA.
Lett. Appl. Microbiol.
14:260-262[Medline].
|
| 21.
|
Mishu, B., and M. J. Blaser.
1993.
The role of Campylobacter jejuni infection in the initiation of Guillain-Barré syndrome.
Clin. Infect. Dis.
17:104-108[Medline].
|
| 22.
|
Moran, A. P., and D. T. O'Malley.
1995.
Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome.
J. Endotoxin Res.
2:233-235.
|
| 23.
|
Nachamkin, I.,
B. M. Allos, and T. Ho.
1998.
Campylobacter species and Guillain-Barré syndrome.
Clin. Microbiol. Rev.
11:555-567[Abstract/Free Full Text].
|
| 24.
|
Nachamkin, I.,
K. Bohachick, and C. M. Patton.
1993.
Flagellin gene typing of Campylobacter jejuni by restriction fragment length polymorphism analysis.
J. Clin. Microbiol.
31:1531-1536[Abstract/Free Full Text].
|
| 25.
|
Nakanishi, H.,
M. Nukina, and R. Sakazaki.
1985.
Serogroups of Campylobacter jejuni and C. coli, p. 70-73.
In
Proceedings of the Symposium on the 100th Anniversary of Japanese Society of Veterinary Medicine: Its Advance and View of Research. Japanese Society of Veterinary Medicine, Tokyo, Japan.
|
| 26.
|
Patton, C. M.,
M. A. Nicholson,
S. M. Ostroff,
A. A. Ries,
I. K. Wachsmuth, and R. V. Tauxe.
1993.
Common somatic O and heat-labile serotypes among Campylobacter strains from sporadic infections in the United States.
J. Clin. Microbiol.
31:1525-1530[Abstract/Free Full Text].
|
| 27.
|
Penner, J. L., and J. N. Hennessy.
1980.
Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens.
J. Clin. Microbiol.
12:732-737[Abstract/Free Full Text].
|
| 28.
|
Rees, J. H.,
S. E. Soudain,
N. A. Gregson, and R. A. Hughes.
1995.
Campylobacter jejuni infection and Guillain-Barré syndrome.
N. Engl. J. Med.
333:1374-1379[Abstract/Free Full Text].
|
| 29.
| Saida, T., S. Kuroki, Q. Hao, M. Nishimura, M. Nukina,
and H. Obayashi. 1997. Campylobacter jejuni isolates
from Japanese patients with Guillain-Barré syndrome. J. Infect. Dis. 176(Suppl. 2):S129-S134.
|
| 30.
|
Salloway, S.,
L. A. Mermel,
M. Seamans,
G. O. Aspinall,
J. E. Nam Shin,
L. A. Kurjanczyk, and J. L. Penner.
1996.
Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3.
Infect. Immun.
64:2945-2949[Abstract].
|
| 31.
|
Sambrook, J. E.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 32.
|
Taylor, D. E., and S.-S. Chau.
1997.
Cloning and nucleotide sequencing of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates.
Antimicrob. Agents Chemother.
41:665-671[Abstract].
|
| 33.
|
Tomb, J.-F.,
O. White,
A. R. Kerlavage,
R. A. Clayton,
G. G. Sutton,
R. D. Fleischmann,
K. A. Ketchum,
H. P. Klenk,
S. Gill,
B. A. Dougherty,
K. Nelson,
J. Quackenbush,
L. Zhou,
E. F. Kirkness,
S. Peterson,
B. Loftus,
D. Richardson,
R. Dodson,
H. G. Khalak,
A. Glodek,
K. McKenney,
L. M. Fitzgerald,
N. Lee,
M. D. Adams, and J. C. Venter.
1997.
The complete genome sequence of the gastric pathogen Helicobacter pylori.
Nature
388:539-547[Medline].
|
| 34.
|
Wang, J. C.
1985.
DNA topoisomerases.
Annu. Rev. Biochem.
54:665-697[Medline].
|
| 35.
|
Wang, Y.,
W. M. Huang, and D. E. Taylor.
1993.
Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.
Antimicrob. Agents Chemother.
37:457-463[Abstract/Free Full Text].
|
| 36.
|
Welsh, J., and M. McClelland.
1990.
Fingerprinting genomes using PCR with arbitrary primers.
Nucleic Acids Res.
18:7213-7218[Abstract/Free Full Text].
|
| 37.
|
Williams, J. G. K.,
M. K. Hanafey,
J. A. Rafalski, and S. V. Tingey.
1993.
Genetic analysis using random amplified polymorphic DNA marker.
Methods Enzymol.
218:704-740[Medline].
|
| 38.
|
Wu, D. Y.,
L. Ugozzoli,
B. K. Pal, and R. B. Wallace.
1989.
Allele-specific enzymatic amplification of -globin genomic DNA for diagnosis of sickle cell anemia.
Proc. Natl. Acad. Sci. USA
86:2725-2760.
|
| 39.
|
Yoshida, H.,
M. Bogaki,
M. Nakamura, and S. Nakamura.
1990.
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.
Antimicrob. Agents Chemother.
34:1271-1272[Abstract/Free Full Text].
|
| 40.
|
Yoshida, H.,
M. Bogaki,
M. Nakamura,
L. M. Yamanaka, and S. Namamura.
1991.
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.
Antimicrob. Agents Chemother.
35:1647-1650[Abstract/Free Full Text].
|
| 41.
|
Yuki, N.,
S. Handa, and T. E. Taki.
1992.
Cross-reactive antigen between nervous tissue and a bacterium elicits Guillain-Barré syndrome: molecular mimicry between ganglioside GM1 and lipopolysaccharide from Penner serotype 19 of Campylobacter jejuni.
Biomed. Res.
13:451-453.
|
| 42.
|
Yuki, N.,
T. Taki,
F. Inagaki,
T. Kasama,
M. Takahashi,
K. Saito,
S. Handa, and T. Miyatake.
1993.
A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure.
J. Exp. Med.
178:1771-1775[Abstract/Free Full Text].
|
| 43.
|
Yuki, N.,
T. Taki,
M. Takahashi,
K. Saito,
T. Tai,
T. Miyatake, and S. Handa.
1994.
Penner serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope.
Infect. Immun.
62:2101-2103[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, December 1998, p. 3567-3573, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
van Bergen, M. A., Simons, G., van der Graaf-van Bloois, L., van Putten, J. P., Rombout, J., Wesley, I., Wagenaar, J. A
(2005). Amplified fragment length polymorphism based identification of genetic markers and novel PCR assay for differentiation of Campylobacter fetus subspecies. J Med Microbiol
54: 1217-1224
[Abstract]
[Full Text]
-
Misawa, N., Kawashima, K., Kondo, F., Ban Mishu Allos, , Blaser, M. J.
(2001). DNA diversity of the wla gene cluster among serotype HS:19 and non-HS:19 Campylobacter jejuni strains. Innate Immunity
7: 349-358
[Abstract]
-
Carvalho, A. C. T., Ruiz-Palacios, G. M., Ramos-Cervantes, P., Cervantes, L.-E., Jiang, X., Pickering, L. K.
(2001). Molecular Characterization of Invasive and Noninvasive Campylobacter jejuni and Campylobacter coli Isolates. J. Clin. Microbiol.
39: 1353-1359
[Abstract]
[Full Text]
-
Tsang, R. S. W., Figueroa, G., Bryden, L., Ng, L.-K.
(2001). Flagella as a Potential Marker for Campylobacter jejuni Strains Associated with Guillain-Barre Syndrome. J. Clin. Microbiol.
39: 762-764
[Abstract]
[Full Text]
-
Tsang, R. S. W., Frosk, P., Johnson;, W. M., Misawa, N., Allos, B. M., Blaser, M. J.
(2000). Heat-Labile Serotyping of Two Campylobacter jejuni Strains Isolated from Patients with Guillain-Barre Syndrome and Belonging to Serotype O19 (Penner). J. Clin. Microbiol.
38: 2021-2022
[Full Text]
-
Wassenaar, T. M., Fry, B. N., Lastovica, A. J., Wagenaar, J. A., Coloe, P. J., Duim, B.
(2000). Genetic Characterization of Campylobacter jejuni O:41 Isolates in Relation with Guillain-Barre Syndrome. J. Clin. Microbiol.
38: 874-876
[Abstract]
[Full Text]
-
Wassenaar, T. M., Newell, D. G.
(2000). Genotyping of Campylobacter spp.. Appl. Environ. Microbiol.
66: 1-9
[Full Text]